



Cite this: *RSC Adv.*, 2019, 9, 29747

# LSGSP: a novel miRNA–disease association prediction model using a Laplacian score of the graphs and space projection federated method

Yi Zhang,<sup>†a</sup> Min Chen,<sup>†a</sup>  Xiaohui Cheng<sup>a</sup> and Zheng Chen<sup>b</sup>

Lots of research findings have indicated that miRNAs (microRNAs) are involved in many important biological processes; their mutations and disorders are closely related to diseases, therefore, determining the associations between human diseases and miRNAs is key to understand pathogenic mechanisms. Existing biological experimental methods for identifying miRNA–disease associations are usually expensive and time consuming. Therefore, the development of efficient and reliable computational methods for identifying disease-related miRNAs has become an important topic in the field of biological research in recent years. In this study, we developed a novel miRNA–disease association prediction model using a Laplacian score of the graphs and space projection federated method (LSGSP). This integrates experimentally validated miRNA–disease associations, disease semantic similarity scores, miRNA functional scores, and miRNA family information to build a new disease similarity network and miRNA similarity network, and then obtains the global similarities of these networks through calculating the Laplacian score of the graphs, based on which the miRNA–disease weighted network can be constructed through combination with the miRNA–disease Boolean network. Finally, the miRNA–disease score was obtained *via* projecting the miRNA space and disease space onto the miRNA–disease weighted network. Compared with several other state-of-the-art methods, using leave-one-out cross validation (LOOCV) to evaluate the accuracy of LSGSP with respect to a benchmark dataset, prediction dataset and compare dataset, LSGSP showed excellent predictive performance with high AUC values of 0.9221, 0.9745 and 0.9194, respectively. In addition, for prostate neoplasms and lung neoplasms, the consistencies between the top 50 predicted miRNAs (obtained from LSGSP) and the results (confirmed from the updated HMDD, miR2Disease, and dbDEMC databases) reached 96% and 100%, respectively. Similarly, for isolated diseases (diseases not associated with any miRNAs), the consistencies between the top 50 predicted miRNAs (obtained from LSGSP) and the results (confirmed from the above-mentioned three databases) reached 98% and 100%, respectively. These results further indicate that LSGSP can effectively predict potential associations between miRNAs and diseases.

Received 18th July 2019  
 Accepted 9th September 2019

DOI: 10.1039/c9ra05554a

[rsc.li/rsc-advances](http://rsc.li/rsc-advances)

## Introduction

MiRNAs are non-coding RNAs of about 20–25 nucleotides,<sup>1</sup> which are widely found in eukaryotes. MiRNAs can account for 1–4% of human genes.<sup>2</sup> MiRNAs normally regulate gene expression at the post-transcriptional level through targeting mRNAs for cleavage or translational inhibition.<sup>3</sup> Many life processes, such as cell growth,<sup>4,5</sup> differentiation,<sup>3</sup> proliferation,<sup>6</sup> aging<sup>7</sup> and signal transduction,<sup>8</sup> have been found to be associated with miRNAs. There is increasing evidence showing that

miRNAs are closely related to complex diseases in humans, and can be regarded as tumor genes or tumor suppressor genes. For example, Mussnich *et al.*<sup>9</sup> found that miR-199a and miR-375 affect the sensitivity of colon cancer cells to cetuximab through targeting PHLPP1, and that mir-106b-25 is related to esophageal neoplastic progression and proliferation *via* the suppression of 2 target genes: p21 and Bim.<sup>10</sup> MiR-367 exerts a tumor-promoting effect through negatively regulating FBXW7 in non-small cell lung cancer (NSCLC), and it could be a potential therapeutic target for NSCLC intervention.<sup>11</sup> MiR-100 and miR-125b are associated with lymph node metastasis in early colorectal cancer, and may be novel biomarkers for the lymph node metastasis of early colorectal cancers with submucosal invasion.<sup>12</sup> Therefore, studying disease-related miRNAs is helpful for analyzing pathogenesis and exploring the rules related to diseases.

<sup>a</sup>School of Information Science and Engineering, Guilin University of Technology, 541004 Guilin, China

<sup>b</sup>School of Computer Science and Technology, Hunan Institute of Technology, 421002 Hengyang, China. E-mail: [chenmin@hnit.edu.cn](mailto:chenmin@hnit.edu.cn)

<sup>†</sup> The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint first authors.



The biological experiments, such as qRT-PCR and microarray profiling, used for discovering the associations between miRNAs and diseases are time consuming and labor intensive.<sup>13,14</sup> Moreover, evidence relating to the associations between miRNAs and diseases discovered through biological experiments is only the tip of the iceberg, meaning that our understanding of the biological functions of miRNAs has a long way to go, although lots of miRNA–disease associations have been explored by scientists. It is an extremely urgent requirement to develop rapid and efficient computational methods to predict disease-related miRNAs to guide biological experiments.<sup>15,16</sup>

Based on the hypothesis that miRNAs with similar functions are often associated with diseases of similar phenotypes,<sup>17–19</sup> Jiang *et al.*<sup>20</sup> used a hypergeometric distribution to predict the associations between miRNAs and diseases. Based on the weighted-*k*-most-similar-neighbour method, Xuan *et al.*<sup>21</sup> proposed HDMP to predict the relationship between miRNA and disease. On the basis of the method proposed by Xuan *et al.*, Han *et al.*<sup>22</sup> proposed DismiPred, which used topology information between nodes. Chen *et al.*<sup>23,24</sup> designed two KNN-based disease association ranking algorithms (RKNNMDA and BLHARMDA). Chen *et al.*<sup>25</sup> used random walks to predict disease-related miRNAs. However, these methods cannot predict diseases without any known related miRNAs. To solve this problem, Chen *et al.*<sup>26</sup> used disease semantic similarity, miRNA similarity, Gaussian interaction profile kernel similarity and experimentally validated miRNA–disease associations to construct a heterogeneous graph approach, named HGIMDA, for revealing potential miRNA–disease associations. Shi *et al.*<sup>27</sup> further integrated miRNA–gene relationships and random walks to predict miRNA–disease associations. Liao *et al.*<sup>28</sup> proposed a new prediction method for disease-related miRNAs using the Laplacian score of the graphs and a random walk method. Chen *et al.*<sup>29</sup> also proposed a new computational method named WBSMDA to uncover potential miRNAs related to multiple complex diseases through integrating known miRNA–disease association, semantic disease similarity, miRNA functional similarity, Gauss's nuclear spectrum of disease and miRNA to obtain final relevance scores for unconfirmed miRNA–disease associations. These methods have achieved good predictive performance and can be used for the prediction of isolated diseases.

Sun *et al.*<sup>30</sup> proposed a method, named NTSMDA, using network topology to predict disease–miRNA associations. Naluri *et al.*<sup>31</sup> designed DISMIRA, a prediction method for disease-related miRNAs, from the two aspects of a maximum weighted matching model and motif-based analyses, respectively. You *et al.*<sup>32</sup> proposed a path-based prediction method named PBMADA through integrating different biological data. Chen *et al.*<sup>33</sup> proposed a bipartite heterogeneous network link prediction method (BHNCN) based on bipartite network co-neighbours to predict miRNA–disease associations. Chen *et al.*<sup>34</sup> proposed a method named NetCBI to predict disease-associated miRNAs using consistency of disease networks. Gu *et al.*<sup>35</sup> and Chen *et al.*<sup>36</sup> predicted potential miRNA–disease associations using bipartite network projections. Le *et al.*<sup>37</sup> applied RWR, PRINCE, PRP and KSM to correlation analysis for

predicting miRNA–disease associations. Chen *et al.*<sup>38</sup> used network distance analysis. Yu *et al.*<sup>39</sup> used global linear neighbours to predict miRNA–disease associations.

Machine learning methods have also entered the field of bioinformatics research.<sup>40–42</sup> Support vector machines (SVMs) were used by Jiang *et al.*,<sup>43</sup> Xu *et al.*,<sup>44</sup> Zeng *et al.*<sup>45</sup> and Wang *et al.*,<sup>46</sup> a logistic model tree was used by Wang *et al.*,<sup>47</sup> and a decision tree was used by Zhao *et al.*;<sup>48</sup> these are excellent classification tools with global optimality and better generalization abilities to predict potential disease-related candidate miRNAs, but such methods require known negative sample information related to disease-related miRNAs that is difficult to obtain. In order to solve the problem of negative sample acquisition, Chen *et al.*<sup>49</sup> used a regularized least squares approach to optimize similarity networks of miRNAs and diseases, respectively, and the final miRNA–disease associations were linear weightings of miRNA similarity scores and disease similarity scores. Restricted Boltzmann machine,<sup>50</sup> auto-encoder,<sup>51</sup> extreme gradient boosting machine,<sup>52</sup> convolutional neural network,<sup>53</sup> kernelized Bayesian matrix factorization,<sup>54,55</sup> non-negative matrix factorization,<sup>56,57</sup> singular value decomposition,<sup>58</sup> Kronecker regularized least squares,<sup>59,60</sup> Laplacian regularized sparse subspace learning,<sup>61</sup> regularized least squares<sup>62</sup> and semi-supervised link integrated prediction methods all were used to infer the relationships between potential diseases and miRNAs with good prediction results. Jiang *et al.*<sup>63</sup> proposed a novel similarity kernel fusion (MDA-SKF) method *via* integrating multiple similarity kernels (three miRNA similarity kernels and three disease similarity kernels) to overcome the limitations through which some initial information may be lost in the process and some noise may exist in the integrated similarity kernel. SKF as an accurate network similarity construction method for MDA-SKF utilized the Laplacian regularized least squares method to uncover potential miRNA–disease associations, and it can be used as an accurate and efficient computational tool for guiding traditional experiments. Zou *et al.*<sup>64</sup> utilized two methods of social network analysis (KATZ and CATAPULT) to predict potential disease-related candidate miRNAs. Li *et al.*<sup>65</sup> utilized recommendation systems to predict associations between environmental factors, miRNAs and diseases. Peng *et al.*<sup>66</sup> combined negative-aware and rating-based recommendation algorithms to predict miRNA–disease associations. Chen *et al.*<sup>67</sup> constructed a similarity network and utilized ensemble learning to combine ranked results, called ensemble learning and link prediction for miRNA–disease association prediction. Chen *et al.*<sup>68</sup> presented a HAMDA model that considered not only the network structure and information propagation but also field-related information to reveal miRNA–disease associations through mixing graph-based recommendation algorithms, and it obtained satisfactory prediction results.

For experimentally verified less well-known miRNA–disease associations and hard-to-obtain negative samples of miRNA–disease associations, Zeng *et al.*,<sup>69</sup> Li *et al.*,<sup>70</sup> Chen *et al.*<sup>71</sup> and Peng *et al.*<sup>72</sup> utilized matrix completion to estimate potential miRNA–disease associations. Chen *et al.*<sup>73</sup> combined a sparse learning method with a heterogeneous graph inference method



for miRNA–disease association predictions. Tang *et al.*<sup>74</sup> fully exploited miRNA functional similarity and disease semantic similarity to achieve the matrix completion of miRNA–disease association through using a dual Laplacian regularization term, which transformed miRNA–disease association prediction into a matrix completion problem. This achieved good prediction effects, only needing experimentally validated miRNA–disease associations, and it provided new ideas for solving the problems that occur when miRNA–disease association data is insufficient.

Although existing computational methods have made outstanding contributions to the field of miRNA–disease association prediction, they still have the following defects:

- (1) These prediction methods are not accurate enough;
- (2) Isolated diseases and new miRNAs (miRNAs not associated with any disease) cannot be predicted; and
- (3) Negative samples of miRNA–disease associations are required.

In order to overcome these defects, our proposed LSGSP model mainly consists of the following four steps to predict miRNA–disease associations:

- (1) Reconstructing similarity networks for diseases and miRNAs, using known miRNA–disease associations, disease semantic similarity, miRNA family information and miRNA functional similarity, respectively;
- (2) Obtaining the global similarity scores of the disease similarity networks and miRNA similarity networks through calculating the Laplacian scores of the graphs;
- (3) Constructing miRNA–disease weight networks on the basis of experimentally verified miRNA–disease Boolean networks combined with global disease similarity networks and global miRNA similarity networks;
- (4) Representing the miRNA–disease association scores using vector projections.

Therefore, LSGSP, as a global approach that does not require negative samples, can simultaneously predict all miRNA–disease associations, and can be used to predict isolated diseases and new miRNAs with good prediction effects in LOOCV and case analysis.

## Materials and methods

### Data preparation

We used three datasets, known as the benchmark dataset, prediction dataset and compare dataset, in this paper. The benchmark dataset, obtained from the ESI in ref. 20, is composed by processed 99 miRNAs, 51 diseases and 225 miRNA–disease associations from an original 271 miRNA–disease associations verified by experiments. The prediction dataset, obtained from the ESI in ref. 19, is composed by processed of 271 miRNAs, 137 diseases and 1395 miRNA–disease associations. The compare dataset,<sup>75</sup> obtained from the HMDDv2.0 database, is composed by processed 495 miRNAs, 383 diseases and 5430 miRNA–disease associations. The matrix MD was used to represent the miRNA–disease associations, and the corresponding value of MD( $i,j$ ) is set to 1 if the miRNA node  $m_i$  is associated with the disease node  $d_j$ , otherwise it is set to 0.

Functional similarity scores between miRNAs obtained from the ESI in ref. 19 were represented by the matrix MM. MiRNA family information obtained from the miRBase database<sup>76</sup> was represented by the matrix MM<sub>fa</sub>. MM<sub>fa</sub>( $i,j$ ) is set to 1 if the miRNA node  $m_i$  is associated with the miRNA node  $m_j$ , otherwise it is set to 0. We used the matrix DD to represent the semantic similarity scores between diseases obtained from the ESI in ref. 66.

**Construction of disease–disease similarity networks.** The accuracy of disease similarity directly affects the effects of miRNA–disease association predictions. Wang *et al.*<sup>19</sup> calculated disease similarity based on semantic information through utilizing the attributes of diseases from the Mesh database, but the accuracy of this method is not so high. Therefore, we used known miRNA–disease associations to reconstruct a disease–disease similarity network based on the semantic matrix DD from Wang *et al.*<sup>19</sup>

Firstly, we used the known matrix MD to calculate the disease similarity information DD<sub>as</sub>, which can be represented by:

$$DD_{as}(i,j) = \begin{cases} \frac{DD_{cm}(d_i, d_j)}{\deg(d_i) + \deg(d_j)} & DD_{cm}(d_i, d_j) \neq 0 \\ 0 & DD_{cm}(d_i, d_j) = 0 \end{cases} \quad (1)$$

where DD<sub>as</sub>( $i,j$ ) denotes the similarity score between disease  $d_i$  and disease  $d_j$ , calculated using the known matrix MD. DD<sub>cm</sub>( $d_i, d_j$ ) denotes the number of miRNAs co-owned by disease  $d_i$  and disease  $d_j$ . deg( $d_i$ ) denotes the degree of disease  $d_i$  in matrix MD. Then, we integrated and made use of the disease similarity score DD( $i,j$ ) from Wang *et al.*<sup>19</sup> using the disease similarity score DD<sub>as</sub>( $i,j$ ) from known miRNA–disease associations to define the final disease similarity score of disease  $d_i$  and disease  $d_j$ , DD<sub>fs</sub>( $i,j$ ) through:

$$DD_{fs}(i,j) = \mu \times DD(i,j) + (1 - \mu) \times DD_{as}(i,j) \quad (2)$$

where  $\mu$  denotes a weight parameter whose value range is set to  $\mu \in (0,1)$ .

**Construction of miRNA–miRNA similarity networks.** The construction of miRNA–miRNA similarity networks is a key step to predict miRNA–disease associations. In order to construct a more accurate miRNA similarity network than the functional similarity score matrix MM for miRNAs from Wang *et al.*<sup>19</sup> we integrated the functional similarity score matrix MM from Wang *et al.*<sup>19</sup> with the miRNAs family information MM<sub>fa</sub> to construct an miRNA–miRNA similarity network:

$$MM_{fs}(i,j) = \theta \times MM(i,j) + (1 - \theta) \times MM_{fa}(i,j) \quad (3)$$

where MM<sub>fs</sub>( $i,j$ ) denotes the final similarity score between the miRNA node  $m_i$  and miRNA node  $m_j$ , which is integrated from the functional similarity score MM( $i,j$ ) from the miRNA node  $m_i$ – $m_j$  and the family information MM<sub>fa</sub>( $i,j$ ) from the miRNA node  $m_i$ – $m_j$ . The weight parameter  $\theta$  has a value range of  $\theta \in (0,1)$ .

**Construction of global similarity based on the Laplacian score of the graphs.** Considering the similarities of a global



network can improve prediction accuracy more effectively than using a local network. The global similarity scores of disease nodes and miRNA nodes were obtained *via* calculating the Laplacian score of the graphs:<sup>77</sup>

$$\min_{\bar{d}} \sum_{ij} \overline{DD}_{fs}(i,j) (\bar{d}_i - \bar{d}_j)^2 + \frac{1-\alpha}{\alpha} \times \sum_i (\bar{d}_i - \bar{d}'_i)^2 \quad (4)$$

where  $\overline{DD}_{fs}$  denotes the normalized matrix of the disease similarity matrix  $DD_{fs}$ , and  $\alpha$  is an equilibrium factor with a range of  $\alpha \in (0,1)$ . The approximate solution of formula (4) is as follows:<sup>77</sup>

$$\bar{d}' = (1-\alpha) \times (I - \alpha \times \overline{DD}_{fs})^{-1} \times d' \quad (5)$$

where  $I$  denotes the identity matrix, and  $d = \{d'_1, d'_2, \dots, d'_{nd}\}$  denotes the initial vector used for representing the similarity between the disease node  $d_k (k=1,2,\dots,nd)$  and other disease nodes, where the corresponding element value of  $d'_k$  is 1 when querying the  $k$ th position in this vector, and the other elements are 0. The Laplacian scores of the graphs between all diseases are represented by the matrix  $DD_{la}$ , which is the collection of vectors  $\bar{d}'$ .

Similarly, the Laplacian score of the graphs between all miRNAs is represented by  $MM_{la}$ , which is as follows:

$$MM_{la} = (1-\beta) \times (I - \beta \times \overline{MM}_{fs})^{-1} \quad (6)$$

where  $\overline{MM}_{fs}$  denotes the normalized matrix of  $MM_{fs}$ , and  $\beta$  denotes an equilibrium factor with a range of  $\beta \in (0,1)$ .

**Construction of disease-miRNA weighted networks.** As mentioned before, the matrix  $MD$ , which represents miRNA-disease associations with experimental verification, is a Boolean network.  $MD$  can only express whether there is an association between the disease and miRNA: it cannot indicate the strength of association.

By integrating the global similarity matrix of disease  $DD_{la}$  and the experimentally verified Boolean network  $MD$  of miRNA-disease associations, the weighted network  $MD_{dl}$  of miRNA-disease associations was constructed based on the global similarity information of diseases.

$$MD_{dl}(i,j) = MD(i,j) + \gamma \times \sum_{k=1, k \neq i}^{nd} DD_{la}(d_k, d_j) \times MD(i,k) / \text{sum}(MD(i, :)) \quad (7)$$

where  $MD_{dl}(i,j)$  denotes the weight between miRNA  $m_i$  and disease  $d_j$ ,  $MD$  denotes the miRNA-disease association matrix,  $\text{sum}(MD(i,:))$  denotes the number of disease nodes associated with miRNA node  $m_i$  in the miRNA-disease association network,  $DD_{la}(d_k, d_j)$  denotes the global similarity score between the disease node  $d_k (k=1,2,\dots,nd)$  and the disease node  $d_j$ , and  $nd$  denotes the number of diseases. Similarly,  $\gamma$  is an equilibrium factor with a range of  $[0,1]$ , as in the previous formula.

Through integrating the global similarity matrix of miRNAs  $MM_{la}$  and the experimentally verified Boolean network  $MD$  of miRNA-disease associations, the weighted network  $MD_{ml}$  of miRNA-disease associations was constructed based on the global similarity information from miRNAs.

$$MD_{ml}(j,i) = MD^T(i,j) + \delta \times \sum_{k=1, k \neq j}^{nm} MM_{la}(m_i, m_k) \times MD(k,j) / \text{sum}(MD(:,j)) \quad (8)$$

where  $MD_{ml}(j,i)$  denotes the weight between the miRNA  $m_i$  and disease  $d_j$ ,  $MD$  denotes the miRNA-disease association matrix,  $MD^T$  denotes the transposed matrix of  $MD$ ,  $\text{sum}(MD(:,j))$  represents the number of miRNAs associated with the disease node  $d_j$ ,  $MM_{la}(m_i, m_k)$  denotes the global similarity score between the miRNA  $m_i$  and miRNA  $m_k (k=1,2,\dots,nm)$ , and  $nm$  denotes the number of miRNAs. As in the previous formula,  $\delta$  is an equilibrium factor with a range of  $[0,1]$ .

#### Calculation of miRNA-disease association prediction scores.

The miRNA-disease association prediction scores in LSGSP were weighted using the spatial projection scores with the two Laplacian similarities of disease and miRNA, respectively. In the flow chart shown in Fig. 1, we took the calculation of the association prediction score between the miRNA node  $m_i$  and the disease node  $d_j$  as an example.

(1) Spatial projection scores based on the Laplacian similarities of diseases:

We used the projected scores of the disease similarity networks in the weighted network  $MD_{ml}$  of miRNA-disease associations to represent the miRNA-disease association scores; the calculation is as follows:

$$MD_{pm}(j,i) = \frac{DD_{la}(j,:) \times MD_{ml}(:,i)}{\|MD_{ml}(:,i)\|} \quad (9)$$

where  $MD_{pm}(j,i)$  denotes the prediction score of the association between the disease  $d_j$  and miRNA  $m_i$ ,  $DD_{la}$  denotes the Laplacian similarity matrix between diseases,  $\|MD_{ml}\|$  denotes the  $MD_{ml}$  norm, which was mentioned before as the weighted network of miRNA-disease associations based on the global similarity information from miRNAs.

(2) spatial projection scores based on the Laplacian similarities of miRNAs:

We used the projected scores of miRNA similarity networks in the weighted network  $MD_{dl}$  to represent the miRNA-disease scores; the calculation is as follows:

$$MD_{pd}(i,j) = \frac{MM_{la}(i,:) \times MD_{dl}(:,j)}{\|MD_{dl}(:,j)\|} \quad (10)$$

where  $MD_{pd}(i,j)$  denotes the prediction score of the association between the miRNA  $m_i$  and disease  $d_j$ , and  $MM_{la}$  denotes the Laplacian similarity matrix of miRNAs. Similarly,  $MD_{dl}$  denotes the  $MD_{dl}$  norm, which was mentioned before as the weighted network of miRNA-disease associations based on global disease similarities.

(3) Final integrated spatial projection scores based on Laplacian similarities of diseases and miRNAs:

Finally, we integrated the spatial projection scores based on the Laplacian similarities of diseases and spatial projection scores based on Laplacian similarities of miRNAs to calculate the final prediction scores, as shown below:

$$MD_{fs}(i,j) = \omega \times MD_{pm}^T(i,j) + (1-\omega) \times MD_{pd}(i,j) \quad (11)$$






Fig. 1 A flowchart showing the whole modelling procedure.

where  $MD_{pm}^T$  denotes the transposed matrix of  $MD_{pm}$  and  $w$  denotes a weighting parameter for  $MD_{pm}$  and  $MD_{pd}$ . The final prediction score  $MD_{fs}(i, j)$  represents the association between the miRNA  $m_i$  and disease  $d_j$ , where a higher score means there

is a higher probability of the miRNA  $m_i$  being associated with the disease  $d_j$ .

Although many researchers have used Laplacian regularization to identify miRNA-disease associations (such as LRSSLMDA,<sup>61</sup> MDA-SKF,<sup>63</sup> and DLRMC<sup>74</sup>), our proposed LSGSP

differs from these research approaches in the following three aspects:

Firstly, it differs in terms of the data preparation process. MDA-SKF used miRNA sequence similarity, but others (LSGSP, LRSSLMDA and DLRMC) did not. LSGSP uses miRNA family information, but others (MDA-SKF, LRSSLMDA and DLRMC) do not.

Secondly, it differs in terms of the purposes of Laplacian regularization utilization. LRSSLMDA, MDA-SKF and DLRMC used Laplacian regularization in the classification decision stage. LRSSLMDA built an objective function from the common miRNA/disease subspace for miRNA/disease feature spaces, an L1-norm constraint and Laplacian regularization, and finally combined these optimization results to attain the final prediction outcomes. MDA-SKF optimized objective Laplacian regularized least squares functions to obtain a predicted association matrix, which uncovered potential miRNA–disease associations. DLRMC used a matrix completion model to calculate the potential missing entries of the miRNA–disease association matrix, and then used dual Laplacian regularization to regularize the miRNA–disease association matrix. The purpose of using Laplacian scores of the graphs in LSGSP is to obtain global network similarity, and for missing miRNA–disease association calculations, a network projection method was used.

Thirdly, it differs in the type of model used. From a classifier perspective, LRSSLMDA, DLRMC and MDA-SKF all utilized a machine learning-based model for miRNA–disease association prediction, which needed to optimize objective functions to obtain prediction results. However, our LSGSP is a network analysis-based computable model, whose missing miRNA–disease association calculations do not need the optimal solution to obtain an objective function. The implementation process of LSGSP is simple, and the prediction results of LSGSP are intuitive and easy to interpret.

## Results

### Parameter selection method

This section mainly discusses the influences of different types of parameters (the weighting parameters  $\theta$  and  $\mu$ , equilibrium parameters  $\alpha$  and  $\beta$ , equilibrium parameters  $\gamma$  and  $\delta$ , and weighting parameter  $\omega$ ) on the prediction performance of LSGSP.

(1) The weight parameters  $\theta$  and  $\mu$  for similarity network construction.

The weight parameter  $\theta$  represents the proportion of the functional similarity scores from Wang *et al.*<sup>19</sup> used for constructing the miRNA similarity network. In order to find the optimal  $\theta$  value, we first set the parameters to fixed values ( $\mu = \alpha = \beta = \gamma = \delta = \omega = 0.5$ ), and changed the value of  $\theta$  from 0.1 to 0.9. Through experiments involving cross-validating and calculating AUC values from the benchmark dataset, we found that the AUC value increased gradually from 0.9006 to 0.9010 when  $\theta$  went from 0.1 to 0.2 and the AUC value decreased gradually from 0.9010 to 0.8892 when  $\theta$  went from 0.2 to 0.9. From the changing curve shown in Fig. 2, the AUC value reached

a maximum when  $\theta = 0.2$ ; therefore, we set  $\theta = 0.2$  to obtain good prediction performance.

The weight parameter  $\mu$  from the disease similarity network indicates the semantic similarity score proportion in the constructed network. On the basis of  $\theta = 0.2$ , we set the rest of the parameters to 0.5 ( $\theta = 0.2, \alpha = \beta = \gamma = \delta = \omega = 0.5$ ). By taking 0.1 as the step size to increase the  $\mu$  value, we found that the AUC value reached a maximum when  $\mu = 0.3$  and the AUC value decreased gradually when  $\mu$  went from 0.3 to 0.9, as shown in Fig. 2. Therefore, we set  $\mu = 0.3$  for good prediction performance.

(2) The equilibrium parameters  $\alpha$  and  $\beta$  for the global similarity network.

The Laplacian similarity equilibrium factor  $\alpha$ , used for the disease similarity network, and the Laplacian similarity equilibrium factor  $\beta$ , used for the miRNA similarity network, were initially set to 0.1 and gradually changed to the same value using a step size of 0.1. The other three types of parameter values were set to fixed values ( $\theta = 0.2, \mu = 0.3, \gamma = \delta = \omega = 0.5$ ) at the same time. When  $\alpha$  and  $\beta$  increased gradually, the AUC value decreased from 0.9093 to 0.8805 gradually in the experiment; therefore the AUC value was optimal when  $\alpha$  and  $\beta$  were set to 0.1.

(3) The equilibrium parameters  $\gamma$  and  $\delta$  for miRNA–disease weight network construction.

Similarly, the third type of parameter included the equilibrium parameters  $\gamma$  and  $\delta$ , used for miRNA–disease weight network construction; their values were set to the same value. The effects of the equilibrium parameters  $\gamma$  and  $\delta$  on LSGSP were tested in the same way as before, and the AUC value reached an optimal value of 0.9113 when  $\gamma$  and  $\delta$  were set to 0.1.

(4) The weight parameter  $\omega$  for spatial projection scores.

Finally, in order to obtain the optimal  $\omega$  value, we gradually increased the value of  $\omega$ , taking 0.1 as the step size. Through experiment, we found that the AUC value increased gradually from 0.9113 to 0.9221 when the value of  $\omega$  was increased from 0.1 to 0.3. When the value of  $\omega$  was increased from 0.3 to 0.9, the




Fig. 2 The influence of parameter variations on the prediction accuracy.



AUC value decreased from 0.9221 to 0.8812. Therefore, we set  $\omega = 0.3$  to obtain the optimal AUC value, which indicated that our prediction results depended more on the spatial projection scores based on the Laplacian similarities of miRNAs.

In summary, our parameter selections from the benchmark dataset were:  $\theta = 0.2$ ;  $\mu = 0.3$ ;  $\alpha = \beta = 0.1$ ;  $\gamma = \delta = 0.1$ ;  $\omega = 0.3$ . By using the same method, the parameter selections from the prediction dataset were:  $\theta = 0.2$ ;  $\mu = 0.1$ ;  $\alpha = \beta = 0.1$ ;  $\gamma = \delta = 0.9$ ;  $\omega = 0.9$ . For the compare dataset, the parameter  $\theta$  was set to 1 because family information was not used. From the same method as used before, the parameter selections from the compare dataset were:  $\theta = 1$ ;  $\mu = 0.1$ ;  $\alpha = \beta = 0.1$ ;  $\gamma = \delta = 0.9$ ;  $\omega = 0.3$ .

### Comparison of the prediction performance in different situations

In this paper, the proposed LSGSP predicted the association scores of miRNAs and diseases using the spatial projection scores of Laplacian similarity. The execution process of LSGSP was as follows:

- (1) Reconstructing the miRNA network using family information;
- (2) Reconstructing the disease network using miRNA–disease association pairs;
- (3) Obtaining the global similarity network using the Laplacian scores;
- (4) Constructing the miRNA–disease weighted network using the global disease similarity network, the global miRNA similarity network and miRNA–disease association information;
- (5) Obtaining the prediction scores using vector space projection.

We evaluate the predictive performance of LSGSP in the following five situations:

- (1) The predictive performance without considering miRNA network reconstruction and disease network reconstruction (LSGSP without NR);
- (2) The predictive performance in the case of reconstructing the miRNA network (LSGSP with MNR);
- (3) The predictive performance in the case of reconstructing the disease network (LSGSP with DNR);
- (4) The predictive performance in the case of reconstructing the miRNA network and disease network without reconstructing the miRNA–disease weight network (LSGSP without MDWN); and
- (5) The predictive performance with all relevant information (LSGSP with all information).

From the results from performing LOOCV shown in Fig. 3, it can be found that the worst predictive performance occurred in the situation of LSGSP without MDWN, where the AUC value was only 0.7809. However, once the miRNA–disease weighted network was constructed, even without considering the reconstruction of the miRNA network and disease network (LSGSP without NR), the AUC value reached 0.8973, which indicated that miRNA–disease weighted network construction had a significant effect on the improvement of prediction performance. In the situation of LSGSP with MNR, the AUC value




Fig. 3 ROC curves and AUC values based on LOOCV in different situations, using the benchmark dataset.

increased from 0.8973 to 0.9135. After reconstructing the disease network through adding structural information relating to the known association network (LSGSP with DNR), the AUC value increased from 0.8973 to 0.9049, and the AUC value in the situation of LSGSP with all information was increased to 0.9221. This shows that LSGSP is commendable at predicting the associations between miRNAs and diseases.

### Comparison with other methods

To further evaluate the predictive performance of LSGSP, we compared it with three classical methods, RLSMDA,<sup>49</sup> IDNC<sup>78</sup> and GSTRW,<sup>79</sup> with the same parameter selection as described in the respective papers. From the results of performing LOOCV on the benchmark dataset, as shown in Fig. 4, the AUC values of RLSMDA, IDNC, GSTRW and LSGSP were 0.8059, 0.8479, 0.8814 and 0.9221, respectively, which showed that LSGSP achieved the best predictive performance, with a value 12.60%, 8.05% and 4.41% higher, respectively, than RLSMDA, IDNC and GSTRW.

To avoid data dependence, the prediction dataset was used to further compare the four methods mentioned above. According to the prediction dataset, with more known




Fig. 4 A comparison of the ROC curves and AUC values from the benchmark dataset.



associations than the benchmark dataset, the accuracy of all four methods greatly improved. The AUC values of RLSMDA, IDNC, GSTRW and LSGSP for the prediction dataset were 0.9232, 0.9434, 0.9512 and 0.9745, respectively, as shown in Fig. 5. The AUC value of LSGSP using the prediction dataset was the highest, with a value 5.26%, 3.19% and 2.39% higher, respectively, than those of RLSMDA, IDNC and GSTRW. The prediction results showed the excellent predictive abilities of LSGSP, mainly due to the use of Laplacian scores and network projection, and LSGSP showed more outstanding advantages with less experimentally verified miRNA–disease associations.

So far, LRSSLMDA,<sup>61</sup> MDA-SKF<sup>63</sup> and DLRMC<sup>74</sup> have obtained good predictive results from the compare dataset using Laplacian regularization to identify miRNA–disease associations. To compare LSGSP with the above-mentioned three methods equally, the AUC values from LSGSP, LRSSLMDA, MDA-SKF and DLRMC given from the compare dataset in Table 1 are the optimal values described in the papers that they belong to. When using the same available experimental data without any family information for LSGSP, LRSSLMDA and DLRMC equally, the AUC value of LSGSP was 0.9194, which was higher than those of LRSSLMDA and DLRMC, as shown in Table 1. MDA-SKF showed the best prediction results, with an optimal AUC value of 0.9576, which were attributed to its accurate SKF network construction method. However, it is unfair to compare the prediction results of MDA-SKF with those from LSGSP directly, because MDA-SKF used extra miRNA sequence similarity information but LSGSP did not. Using SKF for network reconstruction with LSGSP (named LSGSP-SKF) to compare with MDA-SKF under the same experimental conditions, the AUC value was 0.9675, shown as LSGSP-SKF in Table 1; this value was the highest among all methods.

### The prediction of new miRNAs and isolated diseases

The term isolated disease refers to associations between a disease and all miRNAs that are unknown, and the term new miRNA refers to a miRNA with unknown association information related to diseases. The prediction of isolated diseases and new miRNAs can further help scientists to understand the molecular mechanisms of diseases and further reveal the mechanisms behind the occurrences of diseases. Recently,




Fig. 5 A comparison of the ROC curves and AUC values from the prediction dataset.

Table 1 A comparison of the results between LSGSP and the other computational methods

No.	Method	AUC
1	LSGSP	0.9194
2	LRSSLMDA	0.9178
3	DLRMC	0.9174
4	MDA-SKF	0.9576
5	LSGSP-SKF	0.9675

more and more miRNAs have been found with unknown disease-related information. It is urgent to develop efficient calculation methods to predict the associations between new miRNAs and isolated diseases, to reduce the blindness of subsequent biological experiments, to help scientists understand the regulation mechanisms of miRNAs, and to analyze the pathogenesis of diseases at the molecular level.

We implemented LOOCV on the benchmark dataset to evaluate the predictive performance of LSGSP for new miRNAs and isolated diseases. For each new miRNA verified, the associations between the miRNA and all diseases were removed to simulate a new miRNA. The ROC curves and AUC values predicted by LSGSP using the benchmark dataset are shown in Fig. 6, in which the AUC of LSGSP was 0.8597. Similarly, the associations between the disease and all miRNAs were removed to simulate an isolated disease, and the AUC value from the benchmark dataset was 0.7767. According to the prediction results, LSGSP showed excellent predictive performance in predicting new miRNA-related diseases and isolated disease-related miRNAs.

### Case studies

Lots of research evidence has indicated that miRNA mutations and disorders are important causes of disease; thus, the further evaluation of the LSGSP performance for miRNA–disease association prediction is necessary. We selected prostate neoplasms and lung neoplasms as case studies with model training and prediction using the prediction dataset, and then validated all predictions using the updated HMDD, miR2Disease, and dbDEMOC databases, respectively. After that, the predictive abilities of LSGSP for potential miRNA–disease associations and




Fig. 6 Predictions for new miRNAs and isolated diseases using the benchmark dataset.



associations between isolated diseases and miRNAs were analyzed.

### Potential miRNA–disease prediction

Prostate neoplasms are a disease occurring in the male reproductive system, especially common in countries with a severely aging population.<sup>80</sup> Biological experiments have proved some important associations between prostate cancer and miRNAs, such as the epigenetically altered mir-193b target cyclin D1.<sup>81</sup> Rauhala *et al.*<sup>82</sup> found that mir-193b is an epigenetically regulated putative tumor for prostate cancer. Yang *et al.*<sup>83</sup> found that the downregulation of mir-221 and mir-222, which inhibited prostate neoplasm cell proliferation and migration, was mediated in part by SIRT1 activation. Recognizing prostate neoplasm related miRNAs helps to understand the pathogenic mechanism of prostate neoplasms, so as to start treatment at the early stages of the disease.

We used LSGSP for training and prediction, using 34 known associations between prostate neoplasms and miRNAs from the prediction dataset. Only 2 of the top 50 miRNAs predicted to be associated with prostate neoplasms were not confirmed from the updated HMDD, miR2Disease, and dbDEMC databases (shown in Table 2), which were hsa-mir-429 and hsa-mir-7 (ranked 23rd and 50th in predictive results, respectively). However, we found evidence of associations between these two miRNAs and prostate neoplasms upon searching the latest literature. Ouyang *et al.*<sup>84</sup> found that the down-regulation of hsa-mir-429 inhibited the proliferation of prostate cancer cells. Zhou *et al.*<sup>85</sup> identified a total of 130 differentially expressed miRNAs *via* miRNA microarray studies and found that hsa-mir-

7-1 was up-regulated. Sánchez *et al.*<sup>86</sup> proposed synergy between miR-21-5p and miR-7p in the regulation of prostate carcinogenesis. However, the dates of publication for these literature studies were all after the last updates of the three databases, further confirming the effectiveness of LSGSP.

Due to the low detection rate of lung neoplasms, a common lethal disease, they pose a great threat to people's lives,<sup>87,88</sup> especially in developing countries. Recent studies have found that miRNA dysregulation can be considered a diagnostic biomarker for lung neoplasms, such as the expression of mir-1246 and mir-1290, which can be a key driving factor promoting tumor initiation and progression in human non-small cell lung cancer<sup>89</sup>. Lin *et al.*<sup>90</sup> confirmed that mir-324-5p and mir-324-3p play carcinogenic roles with respect to lung cancer. MiR-101 represses lung cancer *via* down-regulating CXCL12.<sup>91</sup> With the discovery of more and more lung neoplasm-related miRNA functions, their study can provide more help for the early detection of lung neoplasms.

We used 72 lung neoplasm–miRNA associations from the prediction dataset to train LSGSP and then predicted the remaining unknown associations. We found supporting evidence for all the first 50 miRNAs related to lung neoplasms predicted by LSGSP using the above-mentioned three databases (as shown in Table 3).

### Isolated disease-related miRNA prediction

Next we validated the predictive ability of LSGSP for isolated diseases, through simulating isolated diseases by removing all known miRNA associations with verified diseases. The predicted results from LSGSP relating to prostate neoplasms and

Table 2 The prediction and confirmation of the top 50 prostatic neoplasm-related candidate miRNAs

Rank	miRNA name	Evidence	Rank	miRNA name	Evidence
1	hsa-mir-18a	dbDEMC	26	hsa-mir-9	dbDEMC
2	hsa-mir-19b	HMDD, dbDEMC, miR2Disease	27	hsa-mir-30d	HMDD, dbDEMC
3	hsa-let-7a	dbDEMC, miR2Disease	28	hsa-mir-15b	dbDEMC
4	hsa-mir-19a	dbDEMC	29	hsa-mir-30b	dbDEMC
5	hsa-mir-34a	HMDD, dbDEMC, miR2Disease	30	hsa-mir-302a	dbDEMC
6	hsa-let-7d	HMDD, dbDEMC, miR2Disease	31	hsa-mir-143	HMDD, dbDEMC, miR2Disease
7	hsa-let-7e	dbDEMC, miR2Disease	32	hsa-mir-218	dbDEMC, miR2Disease
8	hsa-mir-155	dbDEMC	33	hsa-mir-92b	dbDEMC
9	hsa-let-7f	dbDEMC, miR2Disease	34	hsa-mir-302b	dbDEMC
10	hsa-mir-200b	HMDD, dbDEMC	35	hsa-mir-372	dbDEMC
11	hsa-let-7b	HMDD, dbDEMC, miR2Disease	36	hsa-mir-200c	dbDEMC
12	hsa-let-7c	HMDD, dbDEMC, miR2Disease	37	hsa-mir-24	dbDEMC, miR2Disease
13	hsa-mir-20b	dbDEMC	38	hsa-mir-181a	dbDEMC
14	hsa-let-7i	dbDEMC	39	hsa-mir-339	hsa-mir-339-5p
15	hsa-mir-92a	dbDEMC	40	hsa-mir-302c	dbDEMC, miR2Disease
16	hsa-mir-34b	HMDD, dbDEMC	41	hsa-mir-151	dbDEMC
17	hsa-mir-29a	HMDD, dbDEMC, miR2Disease	42	hsa-mir-27a	HMDD, dbDEMC, miR2Disease
18	hsa-mir-141	HMDD, dbDEMC, miR2Disease	43	hsa-mir-215	dbDEMC
19	hsa-mir-18b	dbDEMC	44	hsa-mir-320	dbDEMC, miR2Disease
20	hsa-mir-126	HMDD, dbDEMC, miR2Disease	45	hsa-mir-1	dbDEMC
21	hsa-mir-200a	HMDD, dbDEMC	46	hsa-mir-29c	dbDEMC
22	hsa-mir-125a	dbDEMC, miR2Disease	47	hsa-mir-196a	dbDEMC
23	hsa-mir-429	Unconfirmed	48	hsa-mir-383	dbDEMC
24	hsa-let-7g	dbDEMC, miR2Disease	49	hsa-mir-195	HMDD, dbDEMC, miR2Disease
25	hsa-mir-125b	dbDEMC, miR2Disease	50	hsa-mir-7	Unconfirmed



Table 3 The prediction and confirmation of the top 50 lung neoplasm-related candidate miRNAs

Rank	miRNA name	Evidence	Rank	miRNA name	Evidence
1	hsa-mir-106b	dbDEMC	26	hsa-mir-302b	dbDEMC, miR2Disease
2	hsa-mir-93	dbDEMC	27	hsa-mir-27a	HMDD, dbDEMC
3	hsa-mir-200b	HMDD, dbDEMC	28	hsa-mir-215	dbDEMC
4	hsa-mir-20b	HMDD, dbDEMC	29	hsa-mir-151	dbDEMC
5	hsa-mir-25	dbDEMC	30	hsa-mir-339	dbDEMC, miR2Disease
6	hsa-mir-127	HMDD, dbDEMC	31	hsa-mir-373	dbDEMC
7	hsa-mir-429	dbDEMC	32	hsa-mir-302a	dbDEMC
8	hsa-mir-141	dbDEMC	33	hsa-mir-367	HMDD, dbDEMC, miR2Disease
9	hsa-mir-92b	HMDD, dbDEMC	34	hsa-mir-181a	dbDEMC, miR2Disease
10	hsa-mir-18b	dbDEMC	35	hsa-mir-148a	dbDEMC
11	hsa-mir-98	HMDD, dbDEMC, miR2Disease	36	hsa-mir-15a	dbDEMC
12	hsa-mir-221	HMDD, dbDEMC, miR2Disease	37	hsa-mir-520b	dbDEMC
13	hsa-mir-200a	dbDEMC	38	hsa-mir-103	dbDEMC
14	hsa-mir-200c	dbDEMC, miR2Disease	39	hsa-mir-133a	dbDEMC
15	hsa-mir-222	dbDEMC	40	hsa-mir-372	HMDD, dbDEMC, miR2Disease
16	hsa-mir-16	HMDD	41	hsa-mir-107	HMDD, dbDEMC
17	hsa-mir-10b	HMDD, dbDEMC, miR2Disease	42	hsa-mir-99b	dbDEMC
18	hsa-mir-194	HMDD, dbDEMC, miR2Disease	43	hsa-mir-130a	dbDEMC, miR2Disease
19	hsa-mir-195	dbDEMC, miR2Disease	44	hsa-mir-451	dbDEMC
20	hsa-mir-7	dbDEMC	45	hsa-mir-15b	dbDEMC, miR2Disease
21	hsa-mir-181b	dbDEMC	46	hsa-mir-499	dbDEMC, miR2Disease
22	hsa-mir-320	HMDD, dbDEMC, miR2Disease	47	hsa-mir-204	dbDEMC, miR2Disease
23	hsa-mir-296	dbDEMC	48	hsa-mir-23b	dbDEMC
24	hsa-mir-135b	dbDEMC	49	hsa-mir-302d	dbDEMC
25	hsa-mir-302c	dbDEMC	50	hsa-mir-153	dbDEMC

lung neoplasms from an isolated disease perspective are listed in Table 4 and 5; they were obtained under the conditions of removing the 34 known prostate neoplasm-miRNA associations, where only hsa-mir-302d from the predicted top 50

prostate neoplasm-related miRNAs was not found. Of the predicted top 50 lung neoplasm-related miRNAs, all were found in the above three databases. However, Aghanoori *et al.*<sup>92</sup> found that hsa-mir-302d was down-regulated in lung cancer tissue.

Table 4 The prediction and confirmation of the top 50 isolated disease-related candidate miRNAs (using a prostate neoplasm simulation)

Rank	miRNA name	Evidence	Rank	miRNA name	Evidence
1	hsa-mir-21	HMDD, dbDEMC, miR2Disease	26	hsa-mir-146a	HMDD, dbDEMC, miR2Disease
2	hsa-mir-155	HMDD, dbDEMC, miR2Disease	27	hsa-mir-137	dbDEMC
3	hsa-mir-15a	HMDD, dbDEMC, miR2Disease	28	hsa-let-7a	HMDD, miR2Disease
4	hsa-mir-377	HMDD	29	hsa-mir-205	dbDEMC
5	hsa-mir-373	HMDD, dbDEMC	30	hsa-mir-141	dbDEMC
6	hsa-mir-372	HMDD, dbDEMC, miR2Disease	31	hsa-mir-302a	dbDEMC
7	hsa-mir-29c	HMDD, dbDEMC, miR2Disease	32	hsa-mir-181a	dbDEMC, miR2Disease
8	hsa-mir-34a	dbDEMC	33	hsa-mir-200b	HMDD, dbDEMC
9	hsa-mir-302b	dbDEMC	34	hsa-mir-30a	dbDEMC
10	hsa-mir-451	HMDD, dbDEMC, miR2Disease	35	hsa-mir-143	HMDD, dbDEMC, miR2Disease
11	hsa-mir-184	dbDEMC, miR2Disease	36	hsa-let-7e	dbDEMC
12	hsa-mir-29a	HMDD	37	hsa-let-7b	HMDD, dbDEMC, miR2Disease
13	hsa-mir-16	HMDD, dbDEMC, miR2Disease	38	hsa-mir-223	HMDD, dbDEMC, miR2Disease
14	hsa-mir-19a	dbDEMC	39	hsa-let-7d	HMDD, dbDEMC, miR2Disease
15	hsa-mir-17	HMDD, dbDEMC, miR2Disease	40	hsa-let-7c	HMDD, dbDEMC, miR2Disease
16	hsa-mir-211	dbDEMC	41	hsa-let-7f	dbDEMC, miR2Disease
17	hsa-mir-20a	HMDD, dbDEMC, miR2Disease	42	hsa-let-7i	dbDEMC
18	hsa-mir-125b	dbDEMC	43	hsa-let-7g	dbDEMC, miR2Disease
19	hsa-mir-18a	HMDD, dbDEMC, miR2Disease	44	hsa-mir-9	dbDEMC
20	hsa-mir-10a	dbDEMC, miR2Disease	45	hsa-mir-302c	dbDEMC
21	hsa-mir-221	HMDD, dbDEMC, miR2Disease	46	hsa-mir-15b	HMDD, dbDEMC
22	hsa-mir-19b	dbDEMC	47	hsa-mir-145	HMDD, dbDEMC
23	hsa-mir-92a	HMDD, dbDEMC	48	hsa-mir-92b	dbDEMC
24	hsa-mir-222	HMDD, dbDEMC, miR2Disease	49	hsa-mir-302d	Unconfirmed
25	hsa-mir-181b	HMDD, dbDEMC, miR2Disease	50	hsa-mir-127	dbDEMC



Table 5 The prediction and confirmation of the top 50 isolated disease-related candidate miRNAs (using a lung neoplasm simulation)

Rank	miRNA name	Evidence	Rank	miRNA name	Evidence
1	hsa-mir-21	HMDD, dbDEMC, miR2Disease	26	hsa-mir-18a	HMDD, dbDEMC
2	hsa-mir-373	dbDEMC	27	hsa-mir-137	HMDD, dbDEMC
3	hsa-mir-29c	HMDD, dbDEMC, miR2Disease	28	hsa-mir-146a	HMDD, dbDEMC, miR2Disease
4	hsa-mir-302b	dbDEMC	29	hsa-mir-19b	HMDD, dbDEMC, miR2Disease
5	hsa-mir-451	dbDEMC, miR2Disease	30	hsa-mir-92a	HMDD, dbDEMC
6	hsa-mir-34a	HMDD, dbDEMC	31	hsa-let-7a	HMDD, dbDEMC, miR2Disease
7	hsa-mir-184	dbDEMC	32	hsa-mir-141	dbDEMC, miR2Disease
8	hsa-mir-29a	HMDD, dbDEMC	33	hsa-mir-181a	HMDD, dbDEMC
9	hsa-mir-16	dbDEMC, miR2Disease	34	hsa-mir-30a	HMDD, dbDEMC, miR2Disease
10	hsa-mir-372	dbDEMC	35	hsa-mir-200b	HMDD, dbDEMC
11	hsa-mir-155	HMDD, dbDEMC, miR2Disease	36	hsa-mir-223	HMDD, dbDEMC
12	hsa-mir-148a	HMDD, dbDEMC, miR2Disease	37	hsa-let-7e	HMDD, dbDEMC, miR2Disease
13	hsa-mir-211	dbDEMC	38	hsa-let-7b	HMDD, dbDEMC, miR2Disease
14	hsa-mir-148b	dbDEMC	39	hsa-let-7d	HMDD, dbDEMC, miR2Disease
15	hsa-mir-152	dbDEMC	40	hsa-let-7c	HMDD, dbDEMC, miR2Disease
16	hsa-mir-15a	dbDEMC	41	hsa-let-7i	HMDD, dbDEMC
17	hsa-mir-125b	HMDD, dbDEMC, miR2Disease	42	hsa-let-7f	HMDD, dbDEMC, miR2Disease
18	hsa-mir-17	HMDD, dbDEMC, miR2Disease	43	hsa-let-7g	HMDD, dbDEMC, miR2Disease
19	hsa-mir-19a	HMDD, dbDEMC, miR2Disease	44	hsa-mir-143	HMDD, dbDEMC, miR2Disease
20	hsa-mir-221	HMDD, dbDEMC, miR2Disease	45	hsa-mir-9	HMDD, dbDEMC
21	hsa-mir-10a	dbDEMC	46	hsa-mir-302c	dbDEMC
22	hsa-mir-20a	HMDD, dbDEMC, miR2Disease	47	hsa-mir-302a	dbDEMC
23	hsa-mir-222	HMDD, dbDEMC	48	hsa-mir-92b	HMDD, dbDEMC
24	hsa-mir-205	HMDD, dbDEMC, miR2Disease	49	hsa-mir-302d	dbDEMC
25	hsa-mir-181b	HMDD, dbDEMC	50	hsa-mir-145	HMDD, dbDEMC, miR2Disease

Therefore, supporting evidence for the prediction capabilities of LSGSP for potential disease–miRNA associations and isolated disease–miRNA associations was found from the databases and was validated by the latest literature studies, which means that LSGSP has excellent predictive performance.

## Discussion and conclusions

MiRNAs play a crucial role in the occurrence and development of diseases, therefore studying disease-related miRNAs can help people to understand pathogenesis and explore the rules related to diseases. In recent years, many calculation methods have emerged to extract useful information from massive biomolecular datasets.<sup>93–95</sup> Our proposed LSGSP is one such calculation methods for predicting miRNA–disease associations with some good attributes (such as being easy to implement, being able to predict isolated diseases and new miRNAs, and not requiring negative samples of miRNA–disease associations). Through implementing LOOCV on a benchmark dataset, prediction dataset and compare dataset, AUC values were obtained of 0.9221, 0.9745 and 0.9194, respectively, which proved that the predictive performance of LSGSP was significantly better than other existing methods.

In a case study, LSGSP, when used in selected prostate neoplasm and lung neoplasm cases, achieved 96% and 100% accuracy in potential disease-related miRNA prediction, and 98% and 100% accuracy for isolated disease prediction, respectively, further demonstrating the excellent predictive performance of LSGSP; it also provided supporting evidence for the top 50 predicted disease–miRNA associations in the

updated HMDD, miR2Disease and dbDEMC databases. Supporting evidence for the other miRNA–disease associations not verified in the above three databases was found in the latest literature studies; this demonstrated that LSGSP shows excellent predictive performance for potential associations between miRNAs and diseases. This is helpful for understanding pathogenic mechanisms at the level of miRNAs and finding disease-related miRNAs.

The excellent predictive performance of LSGSP is mainly attributed to the following factors. (1) The good construction of the relationship networks: we reconstructed the disease similarity network and the miRNA similarity network using known miRNA–disease association information, disease semantic similarity, miRNA family information and miRNA functional similarity. (2) The full utilization of network topology characteristics; we used Laplacian scores of the graphs to obtain the global similarities of the miRNA network and the disease network. (3) The accurate construction of weighted networks; we integrated the global similarities of diseases, global similarities of miRNAs and the experimentally validated miRNA–disease Boolean network to construct the miRNA–disease weighted network with a more accurately portrayed miRNA–disease relationship. (4) The use of a calculable projection of network space; we used vector projection to represent the miRNA–disease association degree.

Although LSGSP has achieved creditable predictive results, there are still some capabilities that need to be improved in the future to make the model more efficient and general: (1) the time for selecting the optimal parameters needs to be shortened; and (2) the accuracy of the representation of miRNA–



miRNA similarities needs to be improved further through using biological information data, such as lncRNA-miRNA interactions and miRNA expression profiles.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

The research in this paper has been sponsored by the National Natural Science Foundation of China (Grant No. 61772192, 61672223, 61662017), the Natural Science Foundation of Hunan Province, China (Grant No. 2018JJ2085, 2019JJ40064, 2019JJ40063), the Major Cultivation Projects of Hunan Institute of Technology (Grant No. 2017HGYPY001), and the Science and Technology Innovative Research Team of Hunan Institute of Technology (Grant No. TD18005).

## References

- M. V. Iorio, M. Ferracin, C.-G. Liu, A. Veronese, R. Spizzo, S. Sabbioni, E. Magri, M. Pedriali, M. Fabbri and M. Campiglio, *Cancer Res.*, 2005, **65**, 7065–7070.
- G. Meister and T. Tuschli, *Nature*, 2004, **431**, 343.
- E. A. Miska, *Curr. Opin. Genet. Dev.*, 2005, **15**, 563–568.
- L. Zhu, J. Zhao, J. Wang, C. Hu, J. Peng, R. Luo, C. Zhou, J. Liu, J. Lin and Y. Jin, *PLoS Pathog.*, 2016, **12**, e1005423.
- T. R. Fernando, N. I. Rodriguez-Malave and D. S. Rao, *J. Hematol. Oncol.*, 2012, **5**, 7.
- A. M. Cheng, M. W. Byrom, J. Shelton and L. P. Ford, *Nucleic Acids Res.*, 2005, **33**, 1290–1297.
- P. Xu, M. Guo and B. A. Hay, *Trends Genet.*, 2004, **20**, 617–624.
- R. W. Carthew and E. J. Sontheimer, *Cell*, 2009, **136**, 642–655.
- P. Mussnich, R. Ros, R. Bianco, A. Fusco and D. D'Angelo, *Expert Opin. Ther. Targets*, 2015, **19**, 1017–1026.
- T. Kan, F. Sato, T. Ito, N. Matsumura, S. David, Y. Cheng, R. Agarwal, B. C. Paun, Z. Jin and A. V. Oлару, *Gastroenterology*, 2009, **136**, 1689–1700.
- G. Xiao, X. Gao, X. Sun, C. Yang, B. Zhang, R. Sun, G. Huang, X. Li, J. Liu and N. Du, *Oncol. Rep.*, 2017, **38**, 1190–1198.
- Y. Fujino, S. Takeishi, K. Nishida, K. Okamoto, N. Muguruma, T. Kimura, S. Kitamura, H. Miyamoto, A. Fujimoto and J. Higashijima, *Cancer Sci.*, 2017, **108**, 390–397.
- C. C. Pritchard, H. H. Cheng and M. Tewari, *Nat. Rev. Genet.*, 2012, **13**, 358.
- H. Dong, J. Lei, L. Ding, Y. Wen, H. Ju and X. Zhang, *Chem. Rev.*, 2013, **113**, 6207.
- X. Zeng, X. Zhang and Q. Zou, *Briefings Bioinf.*, 2016, **17**, 193–203.
- X. Chen, D. Xie, Q. Zhao and Z.-H. You, *Briefings Bioinf.*, 2019, **20**, 515–539.
- M. Lu, Q. Zhang, M. Deng, J. Miao, Y. Guo, W. Gao and Q. Cui, *PLoS One*, 2008, **3**, e3420.
- S. Bandyopadhyay, R. Mitra, U. Maulik and M. Q. Zhang, *Silence*, 2010, **1**, 6.
- D. Wang, J. Wang, M. Lu, F. Song and Q. Cui, *Bioinformatics*, 2010, **26**, 1644–1650.
- Q. Jiang, Y. Hao, G. Wang, L. Juan, T. Zhang, M. Teng, Y. Liu and Y. Wang, *BMC Syst. Biol.*, 2010, **4**(Suppl.1), S2.
- P. Xuan, K. Han, M. Guo, Y. Guo, J. Li, J. Ding, Y. Liu, Q. Dai, J. Li and Z. Teng, *PLoS One*, 2013, **8**, e70204.
- K. Han, P. Xuan, J. Ding, Z. Zhao, L. Hui and Y. Zhong, *Genet. Mol. Res.*, 2014, **13**, 2009–2019.
- X. Chen, Q.-F. Wu and G.-Y. Yan, *RNA Biol.*, 2017, **14**, 952–962.
- X. Chen, J.-Y. Cheng and J. Yin, *RNA Biol.*, 2018, **15**, 1192–1205.
- X. Chen, M.-X. Liu and G.-Y. Yan, *Mol. BioSyst.*, 2012, **8**, 2792–2798.
- X. Chen, C. C. Yan, Z. Xu, Z. H. You, H. Yuan and G. Y. Yan, *Oncotarget*, 2016, **7**, 65257–65269.
- H. Shi, J. Xu, G. Zhang, L. Xu, C. Li, L. Wang, Z. Zhao, W. Jiang, Z. Guo and X. Li, *BMC Syst. Biol.*, 2013, **7**, 101.
- M. Chen, X. Lu, B. Liao, Z. Li, L. Cai and C. Gu, *PLoS One*, 2016, **11**, e0166509.
- X. Chen, C. C. Yan, X. Zhang, Z. H. You, L. Deng, Y. Liu, Y. Zhang and Q. Dai, *Sci. Rep.*, 2016, **6**, 21106.
- D. Sun, A. Li, H. Feng and M. Wang, *Mol. BioSyst.*, 2016, **12**, 2224–2232.
- J. J. Nalluri, B. K. Kamapantula, D. Barh, N. Jain, A. Bhattacharya, S. S. de Almeida, R. T. Juca Ramos, A. Silva, V. Azevedo and P. Ghosh, *BMC Genomics*, 2015, **16**, S12.
- Z. H. You, Z. A. Huang, Z. Zhu, G. Y. Yan, Z. W. Li, Z. Wen and X. Chen, *PLoS Comput. Biol.*, 2017, **13**, e1005455.
- M. Chen, Y. Zhang, A. Li, Z. Li, W. Liu and Z. Chen, *Front. Genet.*, 2019, **10**, 385.
- H. Chen and Z. Zhang, *BMC Med. Genomics*, 2013, **6**, 12.
- C. Gu, L. Bo, X. Li and K. Li, *Sci. Rep.*, 2016, **6**, 36054.
- X. Chen, D. Xie, L. Wang, Q. Zhao, Z.-H. You and H. Liu, *Bioinformatics*, 2018, **34**, 3178–3186.
- D. H. Le, *Comput. Biol. Chem.*, 2015, **58**, 139–148.
- X. Chen, L. Y. Wang and L. Huang, *J. Cell. Mol. Med.*, 2018, **22**, 2884–2895.
- S.-P. Yu, C. Liang, Q. Xiao, G.-H. Li, P.-J. Ding and J.-W. Luo, *RNA Biol.*, 2018, **15**, 1215–1227.
- M. Chen, M. Zhong, Z. Li, X. Li and A. Li, *J. Comput. Theor. Nanosci.*, 2015, **12**, 4036–4042.
- M. Chen, Z. Li, Y. Zhang, X. Chen and A. Li, *J. Comput. Theor. Nanosci.*, 2015, **12**, 4890–4894.
- M. Chen, X. He, S. Duan and Y. Deng, *Comb. Chem. High Throughput Screening*, 2017, **20**, 158–163.
- Q. Jiang, G. Wang, T. Zhang and Y. Wang, Predicting human microRNA-disease associations based on support vector machine, in *2010 IEEE International Conference On Bioinformatics and Biomedicine (BIBM)*, 2010, pp. 467–472.
- J. Xu, C.-X. Li, J.-Y. Lv, Y.-S. Li, Y. Xiao, T.-T. Shao, X. Huo, X. Li, Y. Zou and Q.-L. Han, *Mol. Cancer Ther.*, 2011, **10**, 1857–1866.



- 45 X. Zeng, Z. Xuan, Y. Liao and L. Pan, *Biochim. Biophys. Acta*, 2016, **1860**, 2735–2739.
- 46 C.-C. Wang, X. Chen, J. Yin and J. Qu, *RNA Biol.*, 2019, **16**, 257–269.
- 47 L. Wang, Z.-H. You, X. Chen, Y.-M. Li, Y.-N. Dong, L.-P. Li and K. Zheng, *PLoS Comput. Biol.*, 2019, **15**, e1006865.
- 48 Y. Zhao, X. Chen and J. Yin, *Bioinformatics*, 2019, **1**, 9.
- 49 X. Chen and G.-Y. Yan, *Sci. Rep.*, 2014, **4**, 5501.
- 50 X. Chen, C. C. Yan, X. Zhang, Z. Li, L. Deng, Y. Zhang and Q. Dai, *Sci. Rep.*, 2015, **5**, 13877.
- 51 L. Fu and Q. Peng, *Sci. Rep.*, 2017, **7**, 14482.
- 52 X. Chen, L. Huang, D. Xie and Q. Zhao, *Cell Death Dis.*, 2018, **9**, 3.
- 53 P. Xuan, Y. Dong, Y. Guo, T. Zhang and Y. Liu, *Int. J. Mol. Sci.*, 2018, **19**, 3732.
- 54 W. Lan, J. Wang, M. Li, J. Liu, F. X. Wu and Y. Pan, *IEEE/ACM Trans. Comput. Biol. Bioinf.*, 2016, **1**.
- 55 W. Lan, J. Wang, M. Li, J. Liu and Y. Pan, Predicting microRNA-disease associations by integrating multiple biological information, in *IEEE International Conference on Bioinformatics and Biomedicine*, 2015, pp. 183–188.
- 56 Q. Xiao, J. Luo, C. Liang, J. Cai and P. Ding, *Bioinformatics*, 2018, **34**, 239–248.
- 57 Y. Zhong, P. Xuan, X. Wang, T. Zhang, J. Li, Y. Liu and W. Zhang, *Bioinformatics*, 2018, **34**, 267–277.
- 58 C. Pasquier and J. Gardès, *Sci. Rep.*, 2016, **6**, 27036.
- 59 X. Chen, Y. W. Niu, G. H. Wang and G. Y. Yan, *J. Transl. Med.*, 2017, **15**, 251.
- 60 J. Luo, Q. Xiao, C. Liang and P. Ding, *IEEE Access*, 2017, **5**, 2503–2513.
- 61 X. Chen and L. Huang, *PLoS Comput. Biol.*, 2017, **13**, e1005912.
- 62 L. Peng, M. Peng, B. Liao, Q. Xiao, W. Liu, G. Huang and K. Li, *RSC Adv.*, 2017, **7**, 44447–44455.
- 63 M. Chen, B. Liao and Z. Li, *Sci. Rep.*, 2018, **8**, 6481.
- 64 Q. Zou, J. Li, Q. Hong, Z. Lin, Y. Wu, H. Shi and Y. Ju, *BioMed Res. Int.*, 2015, **2015**, 8105.
- 65 J. Li, Z. Wu, F. Cheng, W. Li, G. Liu and Y. Tang, *Sci. Rep.*, 2014, **4**, 5576.
- 66 L. Peng, Y. Chen, N. Ma and X. Chen, *Mol. BioSyst.*, 2017, **13**, 2650–2659.
- 67 X. Chen, Z. Zhou and Y. Zhao, *RNA Biol.*, 2018, **15**, 807–818.
- 68 X. Chen, Y. W. Niu, G. H. Wang and G. Y. Yan, *J. Biomed. Inf.*, 2017, **76**, 50–58.
- 69 X. Zeng, N. Ding, A. Rodríguez-Patón, Z. Lin and Y. Ju, *Curr. Proteomics*, 2016, **13**, 151–157.
- 70 J. Q. Li, Z. H. Rong, X. Chen, G. Y. Yan and Z. H. You, *Oncotarget*, 2017, **8**, 21187–21199.
- 71 X. Chen, L. Wang, J. Qu, N.-N. Guan and J.-Q. Li, *Bioinformatics*, 2018, **34**, 4256–4265.
- 72 L. Peng, M. Peng, B. Liao, G. Huang, W. Liang and K. Li, *Sci. Rep.*, 2017, **7**.
- 73 X. Chen, J. Yin, J. Qu and L. Huang, *PLoS Comput. Biol.*, 2018, **14**, e1006418.
- 74 C. Tang, H. Zhou, X. Zheng, Y. Zhang and X. Sha, *RNA Biol.*, 2019, **16**, 601–611.
- 75 Y. Li, C. Qiu, J. Tu, B. Geng, J. Yang, T. Jiang and Q. Cui, *Nucleic Acids Res.*, 2013, **42**, D1070–D1074.
- 76 A. Kozomara and S. Griffiths-Jones, *Nucleic Acids Res.*, 2011, **39**, D152–D157.
- 77 D. Zhou, O. Bousquet, T. N. Lal, J. Weston and B. Schölkopf, Learning with local and global consistency, in *Advances in neural information processing systems*, 2004.
- 78 M. Chen, Y. Peng, A. Li, Z. Li, Y. Deng, W. Liu, B. Liao and C. Dai, *RSC Adv.*, 2018, **8**, 36675–36690.
- 79 L. Jiang, Y. Ding, J. Tang and F. Guo, *Front. Genet.*, 2018, **9**, 618.
- 80 K. Lefort, G. P. Ostano, M. Mello-Grand, V. Calpini, M. Scatolini, A. Farsetti, G. P. Dotto and G. Chiorino, *Oncotarget*, 2016, **7**, 48011.
- 81 K. M. Kaukonen, H. E. Rauhala, M. Scaravilli, L. Latonen, M. Annala, R. L. Vessella, M. Nykter, T. L. Tammela and T. Visakorpi, *Cancer Med.*, 2015, **4**, 1417–1425.
- 82 H. E. Rauhala, S. E. Jalava, J. Isotalo, H. Bracken, S. Lehmusvaara, T. L. Tammela, H. Oja and T. Visakorpi, *Int. J. Cancer*, 2010, **127**, 1363–1372.
- 83 X. Yang, Y. Yang, R. Gan, L. Zhao, W. Li, H. Zhou, X. Wang, J. Lu and Q. H. Meng, *PLoS One*, 2014, **9**, e98833.
- 84 Y. Ouyang, P. Gao, B. Zhu, X. Chen, F. Lin, X. Wang, J. Wei and H. Zhang, *Mol. Med. Rep.*, 2015, **11**, 1435–1441.
- 85 W. Zhou and D. Wu, *Int. J. Clin. Exp. Med.*, 2016, **9**, 8713–8718.
- 86 C. A. Sánchez, E. I. Andahur, R. Valenzuela, E. A. Castellon, J. A. Fulla, C. G. Ramos and J. C. Triviño, *Oncotarget*, 2016, **7**, 3993.
- 87 S. Temraz, M. Charafeddine, D. Mukherji and A. Shamseddine, *Journal of epidemiology and global health*, 2017, **7**, 161.
- 88 L. A. Torre, R. L. Siegel and A. Jemal, in *Lung cancer and personalized medicine*, Springer, 2016, pp. 1–19.
- 89 W. C. Zhang, T. M. Chin, H. Yang, M. E. Nga, D. P. Lunny, E. K. H. Lim, L. L. Sun, Y. H. Pang, Y. N. Leow and S. R. Y. Malusay, *Nat. Commun.*, 2016, **7**, 11702.
- 90 M. H. Lin, Y. Z. Chen, M. Y. Lee, K. P. Weng, H. T. Chang, S. Y. Yu, B. J. Dong, F. R. Kuo, L. T. Hung and L. F. Liu, *Oncol. Lett.*, 2018, **15**, 9818–9826.
- 91 J. Zhang, J. Liu, Y. Liu, W. Wu, X. Li, Y. Wu, H. Chen, K. Zhang and L. Gu, *Biomed. Pharmacother.*, 2015, **74**, 215–221.
- 92 M.-R. Aghanoori, B. Mirzaei and M. Tavallaei, *Asian Pac. J. Cancer Prev.*, 2014, **15**, 9557–9565.
- 93 G. Huang, F. Yan and D. Tan, *Curr. Protein Pept. Sci.*, 2018, **19**, 562–572.
- 94 G. Huang, K. Feng, X. Li and Y. Peng, *Comb. Chem. High Throughput Screening*, 2016, **19**, 121–128.
- 95 G. Huang and W. Zeng, *MATCH Commun. Math. Comput. Chem.*, 2016, **75**, 717–730.

